Y5 neuropeptide Y receptor overexpression in mice neither affects anxiety- and depression-like behaviours nor seizures but confers moderate hyperactivity

Neuropeptides
Mikkel V OlesenDavid P D Woldbye

Abstract

Neuropeptide Y (NPY) has been implicated in anxiolytic- and antidepressant-like behaviour as well as seizure-suppressant effects in rodents. Although these effects appear to be predominantly mediated via other NPY receptors (Y1 and/or Y2), several studies have also indicated a role for Y5 receptors. Gene therapy using recombinant viral vectors to induce overexpression of NPY, Y1 or Y2 receptors in the hippocampus or amygdala has previously been shown to modulate emotional behaviour and seizures in rodents. The present study explored the potential effects of gene therapy with the Y5 receptor, by testing effects of recombinant adeno-associated viral vector (rAAV) encoding Y5 (rAAV-Y5) in anxiety- and depression-like behaviour as well as in kainate-induced seizures in adult mice. The rAAV-Y5 vector injected into the hippocampus and amygdala induced a pronounced and sustained increase in Y5 receptor mRNA expression and functional Y5 receptor binding, but no significant effects were found with regard to anxiety- and depression-like behaviours or seizure susceptibility. Instead, rAAV-mediated Y5 receptor transgene overexpression resulted in moderate hyperactivity in the open field test. These results do not support a potential role f...Continue Reading

References

Jun 1, 1993·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·M HeiligK T Britton
Nov 11, 1999·Proceedings of the National Academy of Sciences of the United States of America·D J MarshR D Palmiter
Apr 3, 2002·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·John P RedrobeRémi Quirion
May 30, 2002·Neuroscience and Biobehavioral Reviews·Ants KaskRémi Quirion
Oct 18, 2002·Life Sciences·John P RedrobeRémi Quirion
Jul 16, 2003·The European Journal of Neuroscience·Alexandra TschenettGünther Sperk
Aug 20, 2003·The European Journal of Neuroscience·Ramla BenmaamarAntoine Depaulis
Mar 27, 2004·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Cristina RichichiAnnamaria Vezzani
Sep 1, 2004·Neuropeptides·Markus Heilig
Sep 1, 2004·Neuropeptides·D P D Woldbye, M Kokaia
Sep 8, 2004·Journal of Neuroscience Research·Gunnar SørensenDavid P D Woldbye
Dec 8, 2004·Regulatory Peptides·R BenmaamarA Vezzani
Mar 3, 2005·Pharmacology, Biochemistry, and Behavior·Rose-Marie KarlssonJacqueline N Crawley
Jun 28, 2005·Neurobiology of Disease·David P D WoldbyeMerab Kokaia
Sep 30, 2005·The European Journal of Neuroscience·Bouchaïb El BahhWilliam F Colmers
Apr 26, 2006·Proceedings of the National Academy of Sciences of the United States of America·Akane IshiharaTakehiro Fukami
Dec 15, 2006·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Ana P SilvaJoão O Malva
Dec 21, 2007·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Birgitte TiesjemaSusanne E la Fleur
Jan 29, 2008·Recent Patents on CNS Drug Discovery·Sara XapelliJoão O Malva
Jul 12, 2008·The European Journal of Neuroscience·Tim KarlHerbert Herzog
Nov 29, 2008·Experimental Neurology·Andreas T SørensenMerab Kokaia
Apr 30, 2009·Annual Review of Neuroscience·Anatol C Kreitzer
Sep 5, 2009·The Journal of Comparative Neurology·Amanda B RostkowskiJanice H Urban
Sep 29, 2009·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·En-Ju Deborah LinHerbert Herzog
Feb 16, 2010·Neuron·Michael S Fanselow, Hong-Wei Dong
Oct 12, 2010·Journal of Neuroscience Research·S H Christiansen, D P D Woldbye
Mar 5, 2011·Psychopharmacology·Lene S SchmidtAnders Fink-Jensen

❮ Previous
Next ❯

Citations

Nov 12, 2013·Neuropeptides·Viktória Kormos, Balázs Gaszner
Dec 12, 2012·Neuropeptides·Masanobu ItoRemi Quirion
Jun 13, 2013·Peptides·Shunsuke ShimizuKouhei Matsuda
May 24, 2013·PloS One·Emilia RomanoMaria Luisa Scattoni
Nov 19, 2015·The International Journal of Neuropsychopharmacology·Morten JensenBirgitte Holst

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Polyendocrine Syndromes

This feed focuses on a rare genetic condition called Autoimmune Polyendocrine Syndromes, which are characterized by autoantibodies against multiple endocrine organs. This can lead to Type I Diabetes.

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.

Autoimmune Polyendocrinopathies

Autoimmune polyendocrinopathies, also called polyglandular autoimmune syndromes (PGASs), or polyendocrine autoimmune syndromes(PASs), are a heterogeneous group of rare diseases characterized by autoimmune activity against more than one endocrine organ, although non-endocrine organs can be affected. Discover the latest research on autoimmune polyendocrinopathies here.

Amygdala and Midbrain Dopamine

The midbrain dopamine system is widely studied for its involvement in emotional and motivational behavior. Some of these neurons receive information from the amygdala and project throughout the cortex. When the circuit and transmission of dopamine is disrupted symptoms may present. Here is the latest research on the amygdala and midbrain dopamine.

Amygdala: Sensory Processes

Amygdalae, nuclei clusters located in the temporal lobe of the brain, play a role in memory, emotional responses, and decision-making. Here is the latest research on sensory processes in the amygdala.